Literature DB >> 17560332

Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs.

Charles Swanton1, Michela Marani, Olivier Pardo, Patricia H Warne, Gavin Kelly, Erik Sahai, Frédéric Elustondo, Jenny Chang, Jillian Temple, Ahmed A Ahmed, James D Brenton, Julian Downward, Barbara Nicke.   

Abstract

Cytotoxic drug resistance is a major cause of cancer treatment failure. We report an RNA interference screen to identify genes influencing sensitivity of different cancer cell types to chemotherapeutic agents. A set of genes whose targeting leads to resistance to paclitaxel is identified, many of which are involved in the spindle assembly checkpoint. Silencing these genes attenuates paclitaxel-induced mitotic arrest and induces polyploidy in the absence of drug. We also identify a ceramide transport protein, COL4A3BP or CERT, whose downregulation sensitizes cancer cells to multiple cytotoxic agents, potentiating endoplasmic reticulum stress. COL4A3BP expression is increased in drug-resistant cell lines and in residual tumor following paclitaxel treatment of ovarian cancer, suggesting that it could be a target for chemotherapy-resistant cancers.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17560332     DOI: 10.1016/j.ccr.2007.04.011

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  156 in total

Review 1.  Weekly paclitaxel in the treatment of recurrent ovarian cancer.

Authors:  Richard D Baird; David S P Tan; Stan B Kaye
Journal:  Nat Rev Clin Oncol       Date:  2010-08-03       Impact factor: 66.675

Review 2.  Preclinical development of molecular-targeted agents for cancer.

Authors:  Alberto Ocana; Atanasio Pandiella; Lillian L Siu; Ian F Tannock
Journal:  Nat Rev Clin Oncol       Date:  2010-12-07       Impact factor: 66.675

Review 3.  Chemotherapy and signaling: How can targeted therapies supercharge cytotoxic agents?

Authors:  Tetyana V Bagnyukova; Ilya G Serebriiskii; Yan Zhou; Elizabeth A Hopper-Borge; Erica A Golemis; Igor Astsaturov
Journal:  Cancer Biol Ther       Date:  2010-11-01       Impact factor: 4.742

4.  RNAi screening identifies TAK1 as a potential target for the enhanced efficacy of topoisomerase inhibitors.

Authors:  S E Martin; Z-H Wu; K Gehlhaus; T L Jones; Y-W Zhang; R Guha; S Miyamoto; Y Pommier; N J Caplen
Journal:  Curr Cancer Drug Targets       Date:  2011-10       Impact factor: 3.428

5.  Up-regulation of the mitotic checkpoint component Mad1 causes chromosomal instability and resistance to microtubule poisons.

Authors:  Sean D Ryan; Eric M C Britigan; Lauren M Zasadil; Kristen Witte; Anjon Audhya; Avtar Roopra; Beth A Weaver
Journal:  Proc Natl Acad Sci U S A       Date:  2012-07-09       Impact factor: 11.205

Review 6.  Targeting sphingolipid metabolism in head and neck cancer: rational therapeutic potentials.

Authors:  Thomas H Beckham; Saeed Elojeimy; Joseph C Cheng; Lorianne S Turner; Stanley R Hoffman; James S Norris; Xiang Liu
Journal:  Expert Opin Ther Targets       Date:  2010-05       Impact factor: 6.902

Review 7.  Evolving concepts in cancer therapy through targeting sphingolipid metabolism.

Authors:  Jean-Philip Truman; Mónica García-Barros; Lina M Obeid; Yusuf A Hannun
Journal:  Biochim Biophys Acta       Date:  2013-12-30

8.  Acid ceramidase improves the quality of oocytes and embryos and the outcome of in vitro fertilization.

Authors:  Efrat Eliyahu; Nataly Shtraizent; Kurt Martinuzzi; Jason Barritt; Xingxuan He; Hong Wei; Sanjeev Chaubal; Alan B Copperman; Edward H Schuchman
Journal:  FASEB J       Date:  2009-12-09       Impact factor: 5.191

9.  Protein kinase A type II-α regulatory subunit regulates the response of prostate cancer cells to taxane treatment.

Authors:  Evan R Zynda; Vitaliy Matveev; Michael Makhanov; Alexander Chenchik; Eugene S Kandel
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

10.  LAPTM4B facilitates late endosomal ceramide export to control cell death pathways.

Authors:  Tomas Blom; Shiqian Li; Andrea Dichlberger; Nils Bäck; Young Ah Kim; Ursula Loizides-Mangold; Howard Riezman; Robert Bittman; Elina Ikonen
Journal:  Nat Chem Biol       Date:  2015-08-17       Impact factor: 15.040

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.